Scott Berry
Impact in
- Statistics and Probability top 0.1%
- Statistical Methods in Clinical Trials
Papers in
-
- Statistical Methods in Clinical Trials 38
- Advanced Causal Inference Techniques 8
-
- Sports Analytics and Performance 22
- Health Systems, Economic Evaluations, Quality of Life 20
- Co-authors
- Donald A. Berry (22 shared papers)Benjamin R. Saville (6 shared papers)Roger Lewis (7 shared papers)Jason T. Connor (4 shared papers)Kristine R. Broglio (14 shared papers)Jeffrey L. Saver (4 shared papers)Bradley P. Carlin (1 shared paper)Péter Müller (1 shared paper)
- Journals
- JAMA (12 papers)Statistics in Medicine (7 papers)Clinical Trials (7 papers)Journal of the American Statistical Association (5 papers)Pharmaceutical Statistics (4 papers)
- Partner nations
- United StatesUnited KingdomAustralia
In The Last Decade
Scott Berry
172 papers receiving 12.9k citations
Scott Berry's Hit Papers
Peers
Comparison fields: 5 of 194
- Statistics and Probability 1.6k
- Critical Care and Intensive Care Medicine 349
- Infectious Diseases 1.2k
- Pulmonary and Respiratory Medicine 2.0k
- Neurology 943
Countries citing papers authored by Scott Berry
This map shows the geographic impact of Scott Berry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott Berry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott Berry more than expected).
Fields of papers citing papers by Scott Berry
This network shows the impact of papers produced by Scott Berry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott Berry. The network helps show where Scott Berry may publish in the future.
Co-authors
The 25 scholars most cited alongside Scott Berry, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 189 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis Hit paper breakdown → | 2019 | 1005 |
| 2 | Comparison of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation Hit paper breakdown → | 2010 | 941 |
| 3 | Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke Hit paper breakdown → | 2013 | 696 |
| 4 | A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody Hit paper breakdown → | 2021 | 675 |
| 5 | Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19 Hit paper breakdown → | 2020 | 650 |
| 6 | Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer Hit paper breakdown → | 2020 | 579 |
| 7 | 2009 | 541 | |
| 8 | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 Hit paper breakdown → | 2021 | 501 |
| 9 | Use of historical control data for assessing treatment effects in clinical trials Hit paper breakdown → | 2013 | 367 |
| 10 | 2010 | 355 | |
| 11 | The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design Hit paper breakdown → | 2020 | 316 |
| 12 | A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease Hit paper breakdown → | 2021 | 305 |
| 13 | The Platform Trial Hit paper breakdown → | 2015 | 288 |
| 14 | 2016 | 267 | |
| 15 | Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial Hit paper breakdown → | 2021 | 258 |
| 16 | 2016 | 249 | |
| 17 | 2016 | 232 | |
| 18 | Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection Hit paper breakdown → | 2022 | 219 |
| 19 | 2012 | 208 | |
| 20 | 2016 | 178 |
About Scott Berry
Scott Berry is a scholar working on Statistics and Probability, Economics and Econometrics, Management Science and Operations Research, Statistics, Probability and Uncertainty and Infectious Diseases, having authored 189 papers that have together received 13.4k indexed citations. Recurring topics across this work include Statistical Methods in Clinical Trials (38 papers), Sports Analytics and Performance (22 papers), Health Systems, Economic Evaluations, Quality of Life (20 papers), Optimal Experimental Design Methods (10 papers), Advanced Causal Inference Techniques (8 papers), Gas Dynamics and Kinetic Theory (7 papers), COVID-19 Clinical Research Studies (7 papers) and Fluid Dynamics and Turbulent Flows (7 papers). The work is most often cited by research in Statistics and Probability (1.6k citations), Critical Care and Intensive Care Medicine (349 citations), Infectious Diseases (1.2k citations), Pulmonary and Respiratory Medicine (2.0k citations) and Neurology (943 citations). Scott Berry has collaborated with scholars based in United States, United Kingdom and Australia. Frequent co-authors include Donald A. Berry, Benjamin R. Saville, Roger Lewis, Jason T. Connor, Kristine R. Broglio, Jeffrey L. Saver, Bradley P. Carlin, Péter Müller, John D. Carroll and Lee A. Macdonald. Their work appears in journals such as JAMA, Statistics in Medicine, Clinical Trials, Journal of the American Statistical Association and Pharmaceutical Statistics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.